27.92

3.68% 0.99

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $27.92, with a volume of 1.83M. It is up +3.68% in the last 24 hours and down -19.19% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Previous Close:

$26.93

Open:

$27.65

24h Volume:

1.83M

Relative Volume:

0.99

Market Cap:

$2.83B

Revenue:

$352.57M

Net Income/Loss:

$-143.01M

P/E Ratio:

-15.43

EPS:

-1.81

Net Cash Flow:

$-153.40M

1W Performance:

+5.28%

1M Performance:

-19.19%

6M Performance:

+59.36%

1Y Performance:

-2.41%

1-Day Range:

$27.33

$29.26

1-Week Range:

$25.23

$29.26

52-Week Range:

$13.53

$36.44

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (622)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

510

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	27.92	2.73B	352.57M	-143.01M	-153.40M	-1.81
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	12.04B	3.95B	3.34B	15.33
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

08:41 AM

H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval - Yahoo Finance Singapore

08:41 AM

Feb 14, 2026

13 Best Innovative Stocks to Buy According to Wall Street Analysts - Insider Monkey

Feb 14, 2026

Why Beam Therapeutics Inc. stock appeals to analysts2025 Top Gainers & Safe Entry Trade Reports - mfd.ru

Feb 14, 2026

Feb 13, 2026

Wedbush Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail

Feb 13, 2026

Prime Editing and CRISPR Market Set for Explosive Growth at 24.1% - openPR.com

Feb 13, 2026

Feb 12, 2026

Trading Recap: Can Beam Therapeutics Inc sustain its profitabilitySell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn

Feb 12, 2026

Best CRISPR Companies to Buy in 2026 and How to Invest in Them - The Motley Fool

Feb 12, 2026

Beam Therapeutics Secures Standby License for Key Patents - TipRanks

Feb 12, 2026

Buyout Rumor: Will Alector Inc stock hit new highs in YEAR2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn

Feb 12, 2026

Volume Summary: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - baoquankhu1.vn

Feb 12, 2026

Understanding Momentum Shifts in (BEAM) - Stock Traders Daily

Feb 12, 2026

Aug Reactions: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Fed Impact & Verified Technical Trade Signals - baoquankhu1.vn

Feb 12, 2026

Feb 11, 2026

FMR LLC's Strategic Acquisition of Beam Therapeutics Inc. Shares - GuruFocus

Feb 11, 2026

What’s the outlook for Beam Therapeutics Inc.’s sectorJuly 2025 Levels & Fast Gain Swing Trade Alerts - mfd.ru

Feb 11, 2026

Feb 10, 2026